Study Summary
This trial is testing a new CAR-T therapy that targets two proteins found on B-cells to treat adults with B-cell non-Hodgkin lymphoma who have relapsed or are refractory to other treatments.
- Non-Hodgkin's Lymphoma
Treatment Effectiveness
Phase-Based Effectiveness
Study Objectives
2 Primary · 8 Secondary · Reporting Duration: Throughout the first 12 months follow up period completion (3 years)
Trial Safety
Phase-Based Safety
Awards & Highlights
Trial Design
1 Treatment Group
C-CAR039
1 of 1
Experimental Treatment
15 Total Participants · 1 Treatment Group
Primary Treatment: CD19/CD20-directed CAR-T cells · No Placebo Group · Phase 1
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18+ · All Participants · 0 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Frequently Asked Questions
How many participants are engaging in this clinical experiment?
"Affirmative. Clinicaltrials.gov's information reveals that this clinical trial, first advertised on August 9th 2022, is still enrolling patients. The study aims to enrol 15 people from a single medical centre." - Anonymous Online Contributor
Does this clinical experiment currently have an open enrollment period?
"Correct. According to the information found on clinicaltrials.gov, this medical trial started recruiting participants from August 9th 2022 and is still actively doing so. The research requires 15 people at a single site to be enrolled in order for it to succeed." - Anonymous Online Contributor
Has the FDA authorized CD19/CD20-directed CAR-T cells to be utilized by medical professionals?
"Our research team judged the safety of CD19/CD20-directed CAR-T cells to be a 1 due to being in Phase 1, which means there is only preliminary data that supports its efficacy and limited information regarding its safety." - Anonymous Online Contributor
What outcomes is this study aiming to manifest?
"This clinical trial's primary outcome, tracked over a 12-month time frame, will be the incidence of Adverse Events [Safety and Tolerability]. Secondary objectives include monitoring C-CAR039 CAR copy number in peripheral blood with qPCR, measuring maximal plasma concentration of C-CAR039 in peripheral blood (Cmax), and estimating overall response rate by determining both complete response (CR) rate and partial response (PR) rates." - Anonymous Online Contributor